Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  BeyondSpring Inc.    BYSI   KYG108301006

BEYONDSPRING INC.

(BYSI)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryAll NewsPress ReleasesOfficial PublicationsSector news

BeyondSpring : Market Opportunities & Strategies

share with twitter share with LinkedIn share with facebook
03/17/2020 | 02:55pm EDT

Optimizing success in cancer treatment

March 2020 | NASDAQ: BYSI

beyondspringpharma.com

  1. B A Y

S

S

Assessing the Plinabulin opportunity

D

I

A

Q

THE CURRENT CHEMOTHERAPY

THE UNMET NEED IN

THE POTENTIAL

HCP AND PAYER

GO-TO-MARKET

LANDSCAPE

CHEMOTHERAPY-INDUCED

OF PLINABULIN

RESPONSE TO PLINABULIN

PLANS

NEUTROPENIA (CIN)

PRODUCT PROFILE

2

  1. B A Y S S D I A
    Q

beyondspringpharma.com

The chemotherapy market gap

Healthcare professionals (HCPs) consider preventing CIN very important

to ensure patients receive the maximum benefit of chemotherapy1

MONOTHERAPY GRANULOCYTE-COLONY

STIMULATING FACTOR (G-CSF) DOESN'T ALLOW

FOR CHEMOTHERAPY OPTIMIZATION3

20182

CIN

BONE PAIN

remains the #1 reason for

remains significant

chemotherapy disruption2

clinical issue3

2040

SLIGHT CHANGES IN DOSING OR DELIVERY CAN HAVE A DEVASTATING IMPACT ON SURVIVAL4

1A

MONOTHERAPY G-CSF IS SUBOPTIOMAL AND LEAVES A SIGNIFICANT CLINICAL GAP

PLINABULIN + G-CSF HAS POTENTIAL TO ADDRESS THIS IMPORTANT UNMET CLINICAL NEED

1. Proprietary market research, BYSI Summer/Fall 2019. 2. LaLami. 3. Moore. 4. Bonadonna G, Valagussa P, Moliterni A et al. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer.

3

N Engl J Med 1995;332:901-906

CURRENT

CHEMOTHERAPY LANDSCAPE

  1. B A Y S S D I A
    Q

beyondspringpharma.com

Significant opportunities exist to improve the standard of care

for patients on chemotherapy

Chemotherapy remains

THE CORNERSTONE OF TREATMENT

for most cancers

~650,000

U.S. PATIENTS

receive chemotherapy annually1

~1.3 MILLION CYCLES

of G-CSF used annually in the US

MYELOSUPPRESSION is currently an

unavoidable consequence of chemo that impacts patient safety and quality of life

Neutropenia and anemia

Chemotherapy dose delays and reductions

Risk of infection: G-CSF use, associated bone pain

Impaired anti-tumor immunity

Hospitalizations and unscheduled office visits

Red blood cell transfusions and erythropoiesis- stimulating agent rescue

Fatigue

Risk of bleeding: platelet transfusion

5

1. Centers for Disease Control and Prevention. Information for Health Care Providers. Available at: www.cdc.gov/cancer/preventinfections/providers.htm. Accessed February 21, 2020.

beyondspringpharma.com

  1. B A Y

S

S

50%+ growth expected in use of first-line chemotherapy by 2040

Q

I

D

A

The global chemotherapy market will continue to experience aggressive growth

- Globally new cases of cancer are expected to increase from 17M in 2018 to 26M in 2040

- First-line chemo patient growth: 53%

More aggressive approaches, (e.g. Immuno-oncology + chemo will require improved CIN support)

Plinabulin + G-CSF data demonstrate potential to support more aggressive chemotherapy with the potential for improved patient outcomes

Brooke E Wilson, Susannah Jacob, Mei Ling Yap, Jacques Ferlay, Freddie Bray, Michael B Barton; Estimates of global chemotherapy demands and corresponding physician workforce requirements for 2018 and 2040: a population-

6

based study; www.thelancet.com/oncology Published online May 8, 2019 http://dx.doi.org/10.1016/S1470-2045(19)30163-9 1

  1. B A Y S S D I A
    Q

beyondspringpharma.com

Treating CIN is an important priority for HCPs

HOW MUCH OF A PRIORITY IS TREATING CIN

IN RELATION TO OTHER COMPLICATIONS OF CHEMOTHERAPY?

Extreme Moderate Not at all

1%

23%

76%

7

QA08: In a patient's overall treatment plan, how much of a priority is treating CIN relative to other complications of chemotherapy (e.g. liver/renal toxicity, nausea/vomiting, anemia, etc.)?

beyondspringpharma.com

  1. B

A

Y

$7+ billion opportunity in CIN global market

A

S

S

D

I

Q

Plinabulin can potentially be used with each cycle of G-CSF in chemotherapy to provide

improved protection from neutropenia

$5+B/yr:

THE US IS THE LARGEST MARKET FOR CIN

Plinabulin + G-CSF Addressable Market:

  • US: 1.3M G-CSF cycles/year
  • Global: 4M G-CSF cycles/year

CANADA

EU 5

AUSTRALIACHINA

SOUTH KOREA

JAPAN

8

Note: 1 https://onlinelibrary.wiley.com/doi/full/10.3322/caac.21338. G-CSF market growth based on IQVIA data (MIDAS for ex-U.S. and DDM MD for U.S.; Q3 '16 to Q2 '18. Standardized G-CSF units

beyondspringpharma.com

  1. B

A

Y

G-CSF Biosimilars: Plinabulin commercial accelerators

A

S

S

D

I

Q

Combination therapy required to address unmet medical need

Biosimilar success coming at Amgen's expense

Aligns with Plinabulin's combination strategy

Market Share YE '191

  • Increased choice
  • Decrease price
    • Biosimilar list price ~33% below branded
    • Average selling price (ASP) continues to decline for all products
    • The gap shows no sign of slowing

Current difference between branded and biosimilar ASP between $2,400 and $2,800/cycle

All trends favor Plinabulin's combination strategy

Neulasta Family (Amgen)

Fulphila (Mylan)

Udenyca (Coherus)

Other

1 shares approximate; not all G-CSF companies report market share performance 9

by product. Based on company filings and investor conference presentations

THE UNMET NEED

CHEMOTHERAPY WITHOUT COMPROMISE

  1. B A Y S S D I A
    Q

beyondspringpharma.com

Unmet need not addressed by monotherapy G-CSF

Efficacy and safety of chemotherapy compromised by substandard care

Neulasta® after TAC for breast cancer

Efficacy

Neulasta 6.0 mg1

Neulasta 6.0 mg2

n=29

n=61

Efficacy issue

Neutropenia:

Neutropenia (grade 3/4)

96.6%

100%

Grade 3 >0.5 & <1.0

Mean ANC nadir (109/L)

0.255 ± 0.287

0.266

Grade 4 >0.5

Neulasta after chemotherapy

Safety

Neulasta 6.0 mg3

Neulasta 6.0 mg4

n=100

Safety issue

Bone pain (score of 1-10)

59%

71%

Severe bone pain (score of 6-10)

24%

27%

Note: 1 Masuda N et al., Support Care Cancer 23: 2891-2898 (2015). 2 Lee J et al., Annals of Surgical Treatment and Research 94(5): 223-238 (2018). 3 Kirshner et al.,

Comm Onc 4:455-459 (2007). 4 Xu et al., Support Care Cancer 24:723-730 (2016). 5 Lalami et al., Critical Reviews in Oncology / Hematology 120 163-179 (2017). ). 6

O'Regan et al., Clinical Breast Cancer 6(2): 163-168 (2005). 7 Vasey et al., British J Cancer 87: 1072-78 (2002). 8 Alba et al. JCO 22(13): 2587-93 (2002).

Neulasta® is a registered trademark of Amgen, Inc.

11

beyondspringpharma.com

  1. B

A

Y

Monotherapy G-CSF is not enough

A

S

S

D

I

Q

Despite a broad use of monotherapy G-CSFs, the "4Ds" are a vexing clinical challenge for preventing neutropenia

DECREASED

DELAYED

DOWNGRADE

DISCONTINUED

recommended dose

cycles

chemotherapy regimen

chemotherapy

CIN and/or febrile neutropenia may have long-term effects with clinical impact on the overall chemotherapy treatment plan, resulting in dose reductions and/or treatment delays, chemotherapy discontinuation, or a switch to less toxic alternatives, and potentially less effective regimens, leading finally to decreased response and survival rates.1

12

1. Segal et al., 2008; Schwenglenks et al., 2006.

beyondspringpharma.com

  1. B

A

Y

Maintaining dose and dosing schedules are critical for survival

A

S

S

D

I

Q

DOSE REDUCTIONS = DECREASED OVERALL SURVIVAL1

DELAYED CYCLES = DECREASED

OVERALL SURVIVAL2

BREAST CANCER

OVARIAN CANCER

Dose reduction ≥15% (n=408)

Median years (95% Cl)

Dose reduction ≥15% (n=82)

Median years (95% Cl)

2.31 (1.87-2.87)

2.30 (1.67-4.12)

Dose reduction <15% (n=411)

Dose reduction <15% (n=88)

3.67 (3.15-4.19)

3.24 (3.00-NR)

Log-rankP value

Log-rankP value

0.0195

0.0114

.

13

1 . 2. Chirivella I et al. Breast Cancer Res Treat. 2009;114:479-484

  1. B A Y S S D I A
    Q

beyondspringpharma.com

Universal challenge of maintaining therapy

Dose reductions, delays, and missing doses by therapy (even with use of G-CSF)

16,000 patients

Despite broad-base use of monotherapy G-CSF, HCPs still struggle to deliver

On time doses

Full dose chemotherapy

Full course chemotherapy

RESULT:

Chemotherapy is sub-optimized

HCPs recognize the clinical gap

STANDARD REGIMEN COHORT

14

Published, 2015. Per EMR review of 16,233 patients with 6 different tumor types 2007-2011.JNCCN-Journal of the National Comprehensive Cancer Network Volume 13 Number 11 November 2015.

  1. B A Y S S D I A
    Q

beyondspringpharma.com

Compromised therapy: Quantifying the unmet market need

Shrink the Red

Breast; n = 10,435

Dose Reduction2

33%

67%

>= 15% < 15%

Dose Delay2

38%

62%

NSCLC; n = 609

Dose Reduction2

32%

68%

>= 15% < 15%

Dose Delay2

34%

66%

NHL; n = 1,852

Dose Reduction2

44%

56%

>= 15% < 15%

Dose Delay2

36%

64%

IMS PharmMetrics Plus study:

  • 23% of Neulasta cycles were administered on days
    other than the day after chemotherapy3
  • The study included over 200,000 Neulasta cycles from 2 patient databases. Approximately 14,000
    cycles included Neulasta Onpro®3

>= 7 Days

< 7 Days

>= 7 Days

< 7 Days

>= 7 Days

< 7 Days

Note: 1Denduluri N, Patti DA, Wang Y, et al. Dose delays, dose reductions, and relative dose intensity in patients with cancer who received adjuvant or neoadjuvant chemotherapy in community oncology practices. J Natl Compr

Netw. 2015;13(11):1383-1394.2 Based on planned regimen(95% CI). 3Retrospective cohort analysis based on health care claims from IMS PharMetrics Plus and Truven Health Analytics MarketScan® Commercial and Medicare

Supplemental Databases. The collective data include health care claims from private US health plans, covering over 30 million persons annually. The data included all patients ≥ 18 years who, between July 1, 2010, and September

30, 2015, initiated ≥ 1 course of myelosuppressive chemotherapy for a primary solid tumor or non-Hodgkin's lymphoma. All patients who received a selected chemotherapy regimen with a risk of FN and pegfilgrastim prophylaxis in

≥ 1 cycles of chemotherapy were selected for inclusion in the study population. FN requiring inpatient care was identified based on an inpatient admission with a diagnosis (principal or secondary) of neutropenia, fever, or

15

infection using ICD-9 and ICD-10 codes. FN requiring outpatient care was only ascertained based on an encounter in the outpatient setting with a diagnosis of neutropenia, fever, or infection, and-on the same date-code for IV

administration of antimicrobial therapy.

beyondspringpharma.com

  1. B

A

Y

Monotherapy G-CSF unmet medical need - Summary

A

S

S

D

I

Q

Severe neutropenia still at 96 - 100% even with the use of G-CSF for high risk chemo

Severe neutropenia causes RDI reductions

  • RDI reductions = reduced survival

Bone pain is a significant challenge for patients

Monotherapy G-CSF does not have the potential to provide anti-cancer benefits

15% 50%

Reduction in Relative

Reduction in Overall

Dose Intensity

Survival

Clinical evidence indicates that dose reduction is

associated with decreased survival.

A more aggressive approach to CIN is needed.

Combination therapy with Plinabulin can address the

unmet clinical need.

16

PLINABULIN

THE POTENTIAL TO ELEVATE THE STANDARD OF CARE

beyondspringpharma.com

  1. B

A

Y

Plinabulin sets a new standard of care

A

S

S

D

I

Q

Plinabulin + G-CSF has the potential to enhance chemotherapy care in the prevention of neutropenia

Additionally, Plinabulin has demonstrated direct anti-cancer benefits in pre-clinical & clinical trials

REDUCTION OF

SEVERE NEUTROPENIA

Combination prevents Grade 3/4

Neutropenia

82.00%

39%

p = 0.03

50.00%

Peg 6 mg (n=21) Plin 20 mg + Peg 6 mg (n=16)

INCREASED RDI/

POTENTIAL FOR OS

Combination improves RDI: Percent of Patients >85% RDI

93.75%

80.95%

Peg 6 mg

Plin 20 mg + Peg 6 mg

REDUCES BONE

PAIN

Combination reduces bone pain

100%

95%

p < 0.0001

90%

80%

70%

of patients

60%

50%

40%

36%

p < 0.01

%

30%

20%

10%

6%

0%

0%

1

2

3

4

5

6

7

8

At least X days of bone pain

Neulasta 6mg (n=22)

Plinabulin 20mg + Neulasta 6mg (n=16) 18

  1. B A Y S S D I A
    Q

beyondspringpharma.com

Plinabulin has the power to transform the treatment journey

Chemotherapy Without Compromise

WITH LESS

WITH LESS

WITH HIGHER NADIR AND SHORTER

WITH NO

GRADE 3 AND 4 CIN

BONE PAIN

DEJERINE-SOTTAS NEUROPATHY

THROMBOCYTOPENIA

TODAY

WITH PLINABULIN

DECREASED Doses

STABLE Doses

DELAYED Cycles

SUSTAINED Cycles

DOWNGRADE Regimen

STRONGEST Regimen

DISCONTINUED Chemotherapy

STAY the Course

19

1. Data on file. BeyondSpring 2020.

  1. B A Y S S D I A
    Q

beyondspringpharma.com

Plinabulin's broad indication presents a market-changing

opportunity

Plinabulin will be indicated for concurrent administration with a myelosuppressive

chemotherapeutic regimen in patients with non-myeloid malignancies for the prevention of CIN

PLINABULIN WILL BE USED WITH:

ALL G-CSFs

ALL CHEMOTHERAPIES

ALL CANCERS

20

PLINABULIN

MARKET RESEARCH FINDINGS

beyondspringpharma.com

  1. B

A

Y

Market Research Overview (Summer/Fall '19)

A

S

S

D

I

Q

PROJECT BACKGROUND

    • BUSINESS NEEDS
  • BeyondSpring is a US-based, global, clinical-stage biopharmaceutical company developing immuno-oncology therapies
  • Plinabulin, currently in phase III clinical trials, will be used in combination with G-CSF therapies for the prevention of CIN

OBJECTIVES

METHODOLOGY

Assess the potential access and

Phase I - Qualitative Primary Market Research

reimbursement landscape in the US

(National/Regional Payers, n=10)

Provide purchaser and HCP perspective

Phase II - Qualitative Primary Market Research

on Plinabulin in the US

(Oncology Practice Managers/Purchasers, n=10)

Understand how Plinabulin will be

Phase III - Quantitative Primary Market Research

incorporated into clinical practice

(Oncologists, n=110)

22

beyondspringpharma.com

  1. B

A

Y

Product differentiation: Target product profile

A

S

S

D

I

Q

Indication:

Plinabulin is indicated for combination use with G-CSF for the prevention of CIN. Plinabulin is a novel, small molecule which acts in a more rapid fashion than standard of care CIN

High Risk CIN

therapies. Additionally, it has demonstrated anti-cancer properties.

Dosing &

Plinabulin: Administered by 30-minute IV infusion on the same day of chemotherapy

Pegfilgrastim (6 mg): Administered 24 hours after chemotherapy infusion either as a SQ

Administration

administration. A single dose starts 30 minutes after chemotherapy infusion per cycle.

injection or an on-body device. A single dose of pegfilgrastim is given per chemotherapy cycle.

Efficacy &

Plinabulin/pegfilgrastim (6 mg) combination is superior in both efficacy and safety to monotherapy pegfilgrastim (6 mg)

Safety

Study Design: Plinabulin/pegfilgrastim combination was evaluated for superiority vs monotherapy pegfilgrastim in patients who were randomized to receive chemotherapy and

Plinabulin/pegfilgrastim or chemotherapy and pegfilgrastim. Patients were monitored for 4 treatment cycles. All patients were provided best supportive care.

Plinabulin/pegfilgrastim (6 mg) combination

Pegfilgrastim (6 mg):

PREVENTION OF GRADE 4 NEUTROPENIA:

40.9%

62.5%

Duration of Grade 3/4 CIN

0.94 days

1.38 days

Efficacy

MEDIAN ANC NADIR

1.00

0.47

(109 cells/L)

(>50% of patients avoid grade 3 and 4 neutropenia)

Chemotherapy benefits:

>90%

<85%

• SUBJECTS MAINTAINING RDI >85%

6%

12%

• Subjects with dose delays

Anti-cancer

Yes (NSCLC study)

No; pegfilgrastim is a growth factor

Safety

Patients experienced more than 3 days of bone pain

0% (P <.01)

36%

Neutrophil overshoot

31%

52%

23

beyondspringpharma.com

  1. B

A

Y

Oncologist's excitement for Plinabulin

A

S

S

D

I

Q

Most important factors in choosing to use Plinabulin in

combination with a G-CSF:

15%

50%

Reduction in Relative

Reduction in

Dose Intensity

Overall Survival

Increase in median Absolute

Ability to maintain

dose/regimen of

Neutrophil Count (ANC) vs.

Reduction in bone pain

chemotherapy

monotherapy G-CSF

Plinabulin's potential direct anti-cancer effect

24

  1. B A Y S S D I A
    Q

beyondspringpharma.com

Provider Positive excitement for combination therapy with

Plinabulin

Understanding of combination therapy: high

Likelihood to prescribe: high

RECEPTIVITY TOWARDS

LIKELIHOOD TO USE PLINABULIN + G-CSF

COMBINATION THERAPY

COMBINATION THERAPY

Favor mono

Low

Tx

10%

9%

No

Preference

17%

Moderate

25%

High

Favor to

65%

Strongly

favor

combination

74%

QB04: On a scale of 1-9, where 1 = Not at all likely to use and 9 = Extremely likely to use, please rate your likelihood to use PLIN + G-CSF combination therapy

25

QB01: How would you characterize the overall clinical benefit of PLIN vs. G-CSFs?

  1. B A Y S S D I A
    Q

beyondspringpharma.com

Payer market research: CIN Management

Economic results of CIN are more closely monitored; avoidance of cost - hospitalization - is paramount

Payers leave the decision of treatment modality to the HCP

Clinical Concern

  • Infection
  • Sepsis
  • Febrile Neutropenia

Economic Concern

  • ER visits
  • Admission into hospital
  • Prolonged hospitalization
  • Readmission to the hospital

Research indicated that the most compelling attributes of Plinabulin were:

  • Reduction in severe neutropenia
  • Increase in Median ANC Nadir

26

  1. B A Y S S D I A
    Q

beyondspringpharma.com

Provider, patient & payer feedback summary

PATIENTS

  • Cancer is the most stress inducing diagnosis
  • Patients express a strong desire to follow the treatment plan and realize a good outcome
  • Slight changes in the plan can cause great anxiety
  • Patients want to stay the course
  • Improved outcome and quality of life

PROVIDERS

PAYERS

The majority of HCPs found the

value proposition of the Plinabulin +

G-CSF combination compelling and

are highly likely to prescribe

Superior reduction in Grade 3 and 4

neutropenia vs. monotherapy G-CSF

Elimination of G-CSF-induced bone

pain

Increase in Median ANC

Potential reduction of infection and

death

CLEAR AND

COMPELLING RATIONALE

  • The product profile demonstrates significant value for payers to cover Plinabulin as an add-on to G-
    CSF
  • Payers consider chemo and G-CSF- related complications to be purview of the HCP
  • Reduced clinical concern
  • Reduced cost

The potential for improved chemotherapy and improved overall survival

Chemotherapy Without Compromise

27

PLINABULIN

GO-TO-MARKET IMPLICATIONS

beyondspringpharma.com

  1. B

A

Y

Chemotherapy Without Compromise

A

S

S

D

I

Q

Plinabulin's differentiated clinical profile andthe unmet market need enable us to pivot the discussion to

improving the standard of care in chemotherapy

DECREASED

DELAYED

DOWNGRADE

DISCONTINUED

recommended dose

cycles

chemotherapy regimen

chemotherapy

STABLE

SUSTAINED

STRONGEST

STAY THE

DOSE

CYCLES

REGIMEN

COURSE

maintaining >85%

cycles on time

of chemotherapy

complete all cycles

29

  1. B A Y S S D I A
    Q

CLINICAL GAP ANALYSIS

G-CSF monotherapy treatment gap

SCIENTIFIC PLATFORM

  • Plinabulin performance
  • Value proposition & message development

Congress activities & Peer reviewed publications

MARKET SHAPING

Extensive market research

Message resonance

  • Engagement - Targeted customer interactions: KOLs, Payers, Patients
  • Speaker mobilization/Education:
    SOC short fall - 4Ds, 15/50 & OS
  • Reimbursement & coding preparation

beyondspringpharma.com

Key commercial actions

LAUNCH STRATEGY

  • HCPs - 360 Coverage
    • Comprehensive commercial program
    • Broad HCP & Payer coverage
  • Patient support services to ensure ease of use, access and improve care
  • Social media across all verticals
  • U.S. manufacturing to guarantee supply

KEY MESSAGES:

  • Combination therapy superiority
  • Improved ANC & Reduced bone pain
  • 4Ss - improved chemo flexibility

ACHIEVING IMPROVED CARE

Chemotherapy Without

Compromise

  • Greater flexibility in delivering chemotherapy
  • Improved clinical outcomes
  • Superior market performance

SEASONED COMMERCIAL TEAM

  • Complete commercial offering
  • Broad coverage of providers, payers and patients across all channels
  • Outstanding execution

30

beyondspringpharma.com

  1. B

A

Y

Value proposition & Message development

A

S

S

D

I

Q

SCIENTIFIC PLATFORM

  • Reduction in:
    • Grade 3 & 4 CIN
    • Bone Pain
  • Improvement in:
    • Absolute Neutrophil Count (ANC)
    • Compliance and persistency with chemotherapy
  • Potential for:
    • Greater flexibility in chemotherapy care
    • Improved outcomes
    • Prolonged Survival

GLOBAL SCALE

  • Multi-nationaloperations
  • World-wideclinical programs
    • Chemotherapy induced neutropenia
    • Non small cell lung cancer
  • Scalable business model
  • Manufacturing:
    • Dynamic
    • Robust
    • Internationally balanced
    • API and Drug Product

PATIENT CENTERED

  • Clinical programs designed to provide clinically superior cancer care
  • Combination approach is CIN focused on optimizing patient benefit and ease market entry
  • Support programs designed to ensure access
  • Education programs for Providers, Payers and Patients to drive understanding of differentiation and value
  • tailored contracting for launch and long-term access & commercial success

31

beyondspringpharma.com

  1. B

A

Y

Launch strategy: Provider, Payer, Patient

A

S

S

D

I

Q

Provider

Payer

Patient

Promotion

Access:

The Plinabulin Plus™ Patient Services

HCPs - 360 Coverage

National, Regional & IDNs

Co-Pay Assistance Program

High volume G-CSF users

Targeted contracting

Will reduce out-of-pocket costs for

- Top deciles & KOLs

Ensure broad availability

commercially1 insured patients

- Top clinics/hospitals

Awareness, promotion and

Patient Assistance Program (PAP)

Reimbursement Support

contracting: National Account

Managers

Plinabulin will be provided at no cost to

Coding and billing

patients facing financial challenges who

Dedicated field team

Education

meet program criteria2

Education programs

Peer-to-peer Programs

Alternative Funding Support

On-line/in-person

- Peer-to-peer;on-line/in-person

Plinabulin Plus™ work with patients to identify

CME

- CME/Promotional

individual programs that provide financial

Promotional

- MSL teams - clinical support

support through independent organization and

MSL teams - clinical support

foundations

Peer Reviewed Publications

1

Medicare, Medicaid and Federal/state program patients will not be eligible for the commercial co-pay program

32

2

The Patient Assistance Program will not cover the costs related to Plinabulin infusion

  1. B A Y S S D I A
    Q

beyondspringpharma.com

Seasoned commercial team delivering an improved standard

of care; improving chemotherapy

Seasoned leadership team

Experienced in building/scaling organizations and successfully launch products

  • Deep oncology experience
  • 15+ years of Part B experience
  • Multiple specialty and oncology launches

Planning for the Plinabulin launch for over a year

On-going partnership discussions in all major markets

Executed broad-based market research and HCP outreach

Initiated core KOL team identification and buildout

Pre-launch Support

  • Key Account managers
  • Medical Science Liaisons
  • Advisory Boards

Launch Support

  • 60 Oncology Account Managers
  • 6 Regional Sales Directors
  • 6 Key Account Managers
  • 6 Field Reimbursement Liaisons
  • 7 Medical Scientific Liaisons

33

beyondspringpharma.com

  1. B

A

Y

P&L strength enables "go-it-alone" potential in US

A

S

S

D

I

Q

EU is ideal for partnership

US market dynamics

US Strategy

Europe Strategy

Of the that 14 launched in the US…

Of these launches, we have evidence that 11

subsequently

launched in Europe, choosing to…

and P&L strength

Go-It-Alone

Co-Promote

Go-It-Alone

Out-License

provide

71%

29%

27%

73%

n = 10

n = 4

n = 3

n = 8

BeyondSpring with excellent leverage for partnership

Source: ZS analysis; ZEJULA ex-US rights to Takeda and VARUBI US and Canada rights to TerSera. (3) Post-launch, Ariad sold ex-US rights to Incyte prior to

34

Source: Evaluate Pharma as accessed on February 25th, 2019 and company press releases

beyondspringpharma.com

  1. B A Y S S D I A
    Q

Commercial

A growing market

40% increase in

Biosimilars:

chemo cycles by

increase

20401

choice, decrease

price2

Plinabulin success drivers

Clinical

Improving standard of care

4S

Drive

Anti-

Decrease

Improve

Stable dose,

therapy

cancer

in bone

clinical

Sustained Cycles,

for cure4

benefits5

pain6

flow3

Strongest Regimen,

Stay the Course3

1 Wilson B Estimates of global chemotherapy demands and corresponding physician workforce requirements for 2018 and 2040: a population-based study 2 Coherus/Mylan biosimilars priced at a 33%; Sandoz biosimilar priced at a 37%

discount to Amgen's Neulasta (company press releases); ASP has continued to fall for biosimilars since launch (Redbook, CMS, Bernstein analysis) 3 Lalami Y Impact of CIN and FN on cancer treatment outcome: An overview about well-

established and recently emerging clinical data 4 BYSI primary market research 5 Plinabulin P2 study results 6 Blayney, Douglas, et al, Plinabulin, a Novel Small Molecule in Development for Chemotherapy-Induced-Neutropenia (CIN)

35

Prevention, Mobilizes CD34+ Cells through a Mechanism of Action Different from G-CSF and from CXCR4 Inhibition, ASH '18 3 Lalami Y Impact of CIN and FN on cancer treatment outcome: An overview about well-established and recently

emerging clinical data

Disclaimer

BeyondSpring Inc. published this content on 17 March 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 17 March 2020 19:54:02 UTC

share with twitter share with LinkedIn share with facebook
All news about BEYONDSPRING INC.
09/24New Data Highlights BeyondSpring's Plinabulin as a Highly Effective Agent for..
GL
09/22BeyondSpring Appoints Elizabeth Czerepak as Chief Financial Officer
GL
09/17BEYONDSPRING : Corporate Presentation
PU
09/11BeyondSpring to Present at the H.C. Wainwright 22nd Annual Global Investment ..
GL
09/08BeyondSpring Receives Breakthrough Therapy Designations from Both U.S. FDA an..
GL
09/03BeyondSpring Provides Second-Quarter 2020 Financial Results and Business Upda..
GL
08/27BeyondSpring to Host Second-Quarter 2020 Financial Results and Operational Up..
GL
08/18BeyondSpring Appoints Forty Seven, Inc., Co-Founder and Stanford Hematology V..
GL
08/11BeyondSpring Initiates Expanded Access Program with Plinabulin for Patients S..
GL
06/30New Stem Cell-Based Application for BeyondSpring's Plinabulin Presented at IS..
GL
More news
Financials (USD)
Sales 2020 - - -
Net income 2020 -60,7 M - -
Net Debt 2020 - - -
P/E ratio 2020 -6,32x
Yield 2020 -
Capitalization 396 M 396 M -
Capi. / Sales 2020 -
Capi. / Sales 2021 27,4x
Nbr of Employees 61
Free-Float 11,5%
Chart BEYONDSPRING INC.
Duration : Period :
BeyondSpring Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BEYONDSPRING INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Average target price 41,50 $
Last Close Price 13,14 $
Spread / Highest target 250%
Spread / Average Target 216%
Spread / Lowest Target 182%
EPS Revisions
Managers
NameTitle
Lan Huang Chairman & Chief Executive Officer
Richard J. Daly Chief Operating Officer
Dong Heng Liu Chief Financial Officer
Ramon W. Mohanlal Director & Chief Medical Officer
James Tonra Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
BEYONDSPRING INC.-15.23%396
GILEAD SCIENCES, INC.-4.20%78 044
VERTEX PHARMACEUTICALS22.48%69 852
REGENERON PHARMACEUTICALS52.89%60 409
WUXI APPTEC CO., LTD.48.89%34 922
BEIGENE, LTD.70.37%25 528